3:00 PM
Jul 03, 2019
 |  BC Extra  |  Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches.

One of the main limitations of CAR T cell therapy is associated toxicities such as cytokine release syndrome (CRS). Engineering strategies to manage or prevent CRS include external switches controlling CAR activity, safety switches engineered into CAR Ts and CARs engineered for drug-mediated CAR T...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >